Hepatic fibrogenesis and cirrhosis are associated with the activation of the hepatic Ito cell into a proliferating, collagen matrix producing cell. This cell is the major effector during the collagen deposition phases of hepatic fibrosis. Efforts to limit the collagen deposition associated with cirrhosis have been hampered in part by an incomplete understanding of the regulation of Ito cell activation. The long range objective of this laboratory is to identify the intracellular mechanisms that regulate Ito cell activation. Towards that end, the current proposal will specifically focus on the factors which regulate Ito cell proliferation in response to platelet-derived growth factor (PDGF). The activated Ito cell expresses the PDGF surface receptor and thereby becomes responsive to this prototypic mitogen which is present during liver injury and fibrogenesis in vivo. The PDGF signal transduction pathway will be examined with emphasis on the nuclear steps which follow raf and MAPK activation. These two essential PDGF-induced cytoplasmic serine/threonine kinases lead to nuclear fos and jun activation which then dimerize and function as transcription factors. The major fos/jun DNA binding site is a DNA sequence termed the activator protein-1 (AP-1) site. Stimulation of the AP-1 site (present in the regulatory region of numerous genes) is closely linked to cellular proliferation. We have characterized several novel agents capable of potentiating (e.g.- 1.25 dihydroxyvitamin D3 ) or inhibiting (e.g.retinoic acid, prostaglandin E, and lipoxygenase inhibition) the mitogenic response to PDGF by different mechanisms. A detailed examination of their mechanisms of action should provide considerable insight into the central regulatory features of the activation which occurs during hepatic fibrogenesis. Preliminary studies demonstrate that these novel modulators all function at a nuclear level distal to raf and MAPK. The focus of the current proposal will be to dissect the PDGF cascade at the proximal nuclear step which follows raf and MAPK activation. These modulators will be systematically examined for their effects on the critical Ito cell nuclear signalling which is induced by PDGF in vitro as well as following carbon tetrachloride administration and bile duct ligation in vivo (rat models of Ito cell proliferation). The main hypothesis of the current proposal is that: Specific modulators of rat Ito cell proliferation alter AP-1 mediated gene transcription. The agents will be used as tools to specifically examine Ito cell fos/jun activation, AP-1 transcriptional activity and AP-1 binding. These studies should provide insight into the factors which regulate Ito cell activation as it relates to the induction of cell cycle progression and mitogenesis. The findings should ultimately impact on the rational design of anti- fibrogenic therapeutics as well as significantly further our knowledge regarding the fibrotic process in general which is operative in a wide variety of disease states.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK047995-04
Application #
2749512
Study Section
General Medicine A Subcommittee 2 (GMA)
Program Officer
Serrano, Jose
Project Start
1995-08-01
Project End
1999-07-31
Budget Start
1998-09-20
Budget End
1999-07-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Tang, Youcai; Chen, Anping (2014) Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Invest 94:503-16
Chen, Anping; Tang, Youcai; Davis, Victoria et al. (2013) Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology 57:2202-12
Lin, Jianguo; Tang, Youcai; Kang, Qiaohua et al. (2012) Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPAR? activity and attenuating oxidative stress. Br J Pharmacol 166:2212-27
Lin, Jianguo; Tang, Youcai; Kang, Qiaohua et al. (2012) Curcumin eliminates the inhibitory effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro. Lab Invest 92:827-41
Lin, Jianguo; Chen, Anping (2011) Curcumin diminishes the impacts of hyperglycemia on the activation of hepatic stellate cells by suppressing membrane translocation and gene expression of glucose transporter-2. Mol Cell Endocrinol 333:160-71
Tang, Youcai; Chen, Anping (2010) Curcumin protects hepatic stellate cells against leptin-induced activation in vitro by accumulating intracellular lipids. Endocrinology 151:4168-77
Tang, Youcai; Chen, Anping (2010) Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter-4 and increasing glucokinase. Br J Pharmacol 161:1137-49
Kang, Qiaohua; Chen, Anping (2009) Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br J Pharmacol 157:1354-67
Kang, Qiaohua; Chen, Anping (2009) Curcumin inhibits srebp-2 expression in activated hepatic stellate cells in vitro by reducing the activity of specificity protein-1. Endocrinology 150:5384-94
Kang, Qiaohua; Chen, Anping (2009) Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1. Lab Invest 89:1275-90

Showing the most recent 10 out of 28 publications